Advanced Heart Recovery
Our growing program has brought patient-centered care and excellent outcomes to even more communities.
From innovation to impact
2025 Outcomes
The multidisciplinary heart recovery program includes heart failure cardiologists, surgeons, advanced care practitioners, nurse navigators and nurse coordinators who are passionate about offering our patients the latest treatments and personalized care plans. The team’s unwavering dedication to patient-centered care has led to the program’s growth and outstanding outcomes
Accomplishments
- Our left ventricular assist device (LVAD) program has consistently been the largest destination therapy program in the country.
- We were selected as one of the 15 HCM centers by AHA to be a template for the HCM database and future COE designations based on our outstanding outcomes, innovation and clinic volumes.
- The Heart Recovery Center has expanded to multiple locations in our community, providing access to care closer to patients’ homes and now follows over 6,000 advanced heart failure patients.
- Community outreach and education to North Texas and Southern Oklahoma first responders drove awareness on caring for LVAD patients.
- Our emergency medical services liaison partnered with the LVAD team to develop a comprehensive and structured training program in response to the growing need for advanced cardiovascular care education in rural areas. This initiative enhanced first responder preparedness across North Texas and in underserved rural communities.
- Our state-of-the-art comprehensive cardiogenic shock protocol and multidisciplinary shock team has become a model of caring being adopted by other centers nationwide.
- Over the past 12-month period, we experienced a 24% improvement in survival to discharge in our Impella 5.5 population, ending the calendar year with an 82% survival to discharge. Building on that success, The Heart Hospital expanded the use of Impella 5.5, performing the first case in Denton in April 2025.
- Our heart recovery team has aggressively worked to lower the rates of driveline infection. Their efforts resulted in a 25% reduction in the incidence of driveline infections in the first quarter of 2025 compared to the first quarter of 2024.
Recognition
- ELSO Gold Center of Excellence
- Center of Excellence for Sarcoidosis by the Foundation for Sarcoidosis Research
Research
- We are the top contributor in the American Heart Association and National Cardiogenic Shock Work Group registries.
- Plano is one of the five facilities in Texas granted as a site for the CRISPR gene editing technology amyloidosis trial, MAGNITUDE, offering a potentially curative therapy for TTR amyloid.
- The INNOVATE trial is looking at a novel smaller LVAD device, the BrioVAD® system as compared to the current Heart Mate III device.
- We participated in the ODYSSEY HCM trial, the largest and longest duration study to-date of patients with non-obstructive HCM. We have seen a meaningful impact on improving quality of life for patients living with this condition.
- We enrolled the first patient in the state of Texas for TEAM HF, an innovative heart failure study for consideration of advanced therapies in patients who are in ambulatory settings with an advanced heart failure phenotype.
ECMO OUTCOMES
Plano
ELSO
EXTRACORPOREAL MEMBRANE OXYGENATION SURVIVAL
80
70
60
50
40
30
20
10
0
0
%
0
%
Cardiac
Survival
0
%
0
%
PULMONARY
SURVIVAL
SURVIVAL
0
%
0
%
ECPR
SURVIVAL
0
%
0
%
RVAD
SURVIVAL
SURVIVAL
One of our
LVAD patients
Innovations
- The heart recovery team is implementing virtual care platforms and remote patient monitoring technologies to address the increasing demand for chronic heart failure management. These initiatives are designed to expand clinical capacity, optimize resource utilization and enhance patient quality of life—ultimately driving improved clinical outcomes.
- The creation of a new clinic space, including an infusion center, offers increased patient access and a higher level of care than can be provided in an outpatient cardiology setting, helping to avoid hospitalizations.
- Offering the newest medications and access to clinical trials at our outpatient specialty clinics has improved patients’ access to the latest amyloidosis treatment options.
- The drive to discover is team-wide. A heart recovery program nurse-driven abstract, accepted at the Heart Failure Society of America Annual Scientific Meeting, revealed that in patients who received mavacamten (Camzyos) for the treatment of hypertrophic cardiomyopathy, all demonstrated a clinically meaningful reduction in left ventricular outflow tract (LVOT) gradient. Additionally, 91% exhibited an improvement in quality of life, as evidenced by an increase in their Kansas City Cardiomyopathy Questionnaire (KCCQ) scores.
Quality awards 2025
Achievements placing us among the elite
Best Hospitals 2025-2026
No. 30 Cardiology and
Heart & Vascular Surgery
Heart & Vascular Surgery
The Society of Thoracic Surgeons
Plano: 3 Stars in All 6 Categories
Denton: 3 Stars in 2 Categories
Denton: 3 Stars in 2 Categories
Vascular Verification Program
Dallas and Plano
High Performing Hospitals - Plano
Abdominal Aortic Aneurysm Repair, Aortic Valve Surgery, Heart Arrhythmia, Heart Attack, Heart Bypass Surgery, Heart Failure, Lung Cancer Surgery, Pacemaker Implantation, Transcatheter Aortic Valve Replacement
Comprehensive Cardiac Center
Dallas and Plano
5-Star Rating
Plano
Denton
Denton
Pinnacle and Guardian of Excellence Awards
Dallas, Denton and Plano
Gold Center of Excellence
Plano
High Performing Hospitals - Dallas
Abdominal Aortic Aneurysm Repair, Heart Arrhythmia, Heart Attack, Pacemaker Implantation, Transcatheter Aortic Valve Replacement
Gold Level Award
Office of Professionalism and Well-being
2024 Premier Top 50 Cardiovascular Hospital
Plano
High Performing Hospitals - Denton
Heart Bypass Surgery
20th consecutive Grade “A”
Dallas
Magnet with Distinction Nursing Designation
Plano
3-Stars
Dallas and Plano
Magnet Pathway Designation
Denton
Magnet Nursing Designation
Dallas
Previous
Next